Authorization

Novartis: Cosentyx Shows Long-lasting Efficacy In FUTURE 5 Trial - Quick Facts

(RTTNews) - Novartis (NVS) said new data from the FUTURE 5 trial demonstrated that 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose) of psoriatic arthritis patients treated with Cosentyx found no radiographic progression at 2 years. Clinical responses were also maintained throughout the duration of the study.

FUTURE 5 is a Phase III, randomized, double-blind, placebo-controlled study evaluating Cosentyx on radiographic progression across 2 years in PsA patients. In the study, 996 adults with active PsA were randomized to receive subcutaneous Cosentyx 300 mg.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Июнь 2019    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
24252627282930